Current portfolio

We unlock value from market dislocations and complex opportunities, investing across a broad range of sectors and stages. This strategy has delivered a 33% IRR on all realised investments over 27 years.

Portfolio

Positive Impact Investing

We unlock value from market dislocations and complex opportunities, investing across a broad range of sectors and stages. This strategy has delivered a 33% IRR on all realised investments over 27 years.

Atlantic SuperConnection

One of the world’s largest green energy projects, ASC is developing a 1,600km subsea cable to bring 1.8 GW of geothermal and hydro-electric power from Iceland to the UK.

Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics is a clinical-stage bioresearch company developing IRX-2, a new immunotherapy for cancer.

 

REG Technologies

REG Technologies enables insurance businesses to seamlessly meet their legal and regulatory requirements by monitoring all of a business’s counterparties in real time with very user friendly and efficient software.

Pension Insurance Corporation

Founded by Edi and Danny Truell in 2006, Pension Insurance Corporation insures UK defined benefit pensions, protecting the pensions of over 270,000 people. It is a leading market player, and as of 30th June 2021 had grown to over £47bn of financial investments.

Telent

Telent is a leading technology company, specialising in the design, installation and maintenance of the UK’s digital infrastructure. Segments include fiberoptic broadband, 5G networks, cyber security, and data centres.

essDocs

essDocs is a software company enabling paperless global trade. Over 60,000 businesses worldwide use essDocs to digitise their trade and finance documents and processes.

Ptarmigan Health Destinations

Having acquired a unique high-altitude Alpine land bank between Verbier and Zermatt, Health Destinations is transforming the beautiful Evolène valley into an exclusive, sustainable world-class Alpine health destination.

ViroCell

ViroCell Biologics manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies (CGTs) to enter clinical trials.

Disruptive Capital Acquisitions Company Ltd

Disruptive Capital Acquisition Company Ltd aims to combine with a financial services company which has a conservative profile and potential for strong and sustainable long-term growth.